NASDAQ · WHWK
Whitehawk Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for WHWK: Nov 5, 2026
Whitehawk Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.26.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.23 | $-0.20 | $-0.27 | 4 |
| Dec 2026 | $-0.23 | $-0.13 | $-0.27 | 4 |
| Mar 2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Jun 2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Sep 14, 11:07 AM EDTWhitehawk Therapeutics: PTK7 Stability Supports ADC Development In EGFR Wild-Type NSCLC(RTTNews) – Whitehawk Therapeutics, Inc. (WHWK) presented new real-world analyses showing that PTK7 expression remains durable and treatment-agnostic in patients with EGFR wild-type non-small cell lung cancer, reinforcing its relevance as a next-generation antibody-drug conjugate
- Zacks · Aug 28, 12:00 PM EDTWhat Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Aug 26, 9:55 AM EDTWall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should KnowThe mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Fintel · Apr 27, 11:59 PM EDTWhitehawk Therapeutics (WHWK) Price Target Increased by 10.29% to 6.38The average one-year price target for Whitehawk Therapeutics (NasdaqCM:WHWK) has been revised to $6.38 / share. This is an increase of 10.29% from the prior estimate of $5.78 dated April 12, 2026. The price target is an average of many targets provided by anal
- Fintel · Apr 16, 8:05 PM EDTCitizens Initiates Coverage of Whitehawk Therapeutics (WHWK) with Market Outperform RecommendationFintel reports that on April 16, 2026, Citizens initiated coverage of Whitehawk Therapeutics (NasdaqCM:WHWK) with a Market Outperform recommendation. Analyst Price Forecast Suggests 36.97% Upside
- Fintel · Mar 27, 10:33 AM EDTWhitehawk Therapeutics (WHWK) Price Target Increased by 13.33% to 5.78The average one-year price target for Whitehawk Therapeutics (NasdaqCM:WHWK) has been revised to $5.78 / share. This is an increase of 13.33% from the prior estimate of $5.10 dated February 21, 2026. The price target is an average of many targets provided by a
- Fintel · Feb 25, 3:27 PM ESTWhitehawk Therapeutics (WHWK) Price Target Increased by 11.11% to 5.10The average one-year price target for Whitehawk Therapeutics (NasdaqCM:WHWK) has been revised to $5.10 / share. This is an increase of 11.11% from the prior estimate of $4.59 dated February 1, 2026. The price target is an average of many targets provided by an
- Zacks · Feb 18, 9:41 AM ESTTempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
- Zacks · Feb 13, 9:33 AM ESTShould You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release?In preliminary, unaudited financial results, TEM posts 83% revenue growth and record data sales in 2025, but valuation and ongoing GAAP losses cloud the outlook before Q4 earnings.
- Fintel · Jan 14, 7:12 AM ESTWhitehawk Therapeutics (WHWK) Price Target Increased by 125.00% to 4.59The average one-year price target for Whitehawk Therapeutics (NasdaqCM:WHWK) has been revised to $4.59 / share. This is an increase of 125.00% from the prior estimate of $2.04 dated December 18, 2025. The price target is an average of many targets provided by
- Fintel · Dec 22, 7:04 PM ESTJones Trading Initiates Coverage of Whitehawk Therapeutics (WHWK) with Buy RecommendationFintel reports that on December 22, 2025, Jones Trading initiated coverage of Whitehawk Therapeutics (NasdaqCM:WHWK) with a Buy recommendation. Analyst Price Forecast Suggests 17.74% Downside
- Zacks · Oct 17, 9:45 AM EDTTempus AI Fuels Growth Through Strategic Biotech CollaborationsTEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Whitehawk Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.